Please use this identifier to cite or link to this item:
http://10.1.7.192:80/jspui/handle/123456789/5311
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mehta, Priti | - |
dc.date.accessioned | 2015-01-21T05:36:53Z | - |
dc.date.available | 2015-01-21T05:36:53Z | - |
dc.date.issued | 2014 | - |
dc.identifier.uri | http://hdl.handle.net/123456789/5311 | - |
dc.description.abstract | Milnacipran hydrochloride is an antidepressant drug, belonging to a class of selective serotonin re-uptake inhibitors. Unknown impurity in active pharmaceutical ingredient and pharmaceutical formulation of Milnacipran hydrochloride was found to be 0.08% and 0.12%, respectively, by peak area, with sensitive, isocratic RP-HPLC method. As per revised guidelines of International Conference on Harmonization Q3A (R2) and Q3B (R2), impurity profiling should be done for drug substances and drug products to identify and characterize all the unknown impurities that are present at level above 0.05%. This unknown impurity was targeted and isolated by developed Prep-HPLC method. The isolated impurity is characterized as 1-phenyl-3-azabicyclo [3.1.0] hexan-2-one using spectroscopic techniques like FT-IR, Mass, and NMR. The origin of the impurity is also postulated by proposing the plausible mechanism of formation. | en_US |
dc.publisher | Taylor & Francis Group | en_US |
dc.relation.ispartofseries | IPFP0119; | - |
dc.subject | characterization, FT-IR | en_US |
dc.subject | liquid chromatography | en_US |
dc.subject | identification | en_US |
dc.subject | NMR spectroscopy | en_US |
dc.subject | unknown impurity | en_US |
dc.title | Isolation and Characterization of Related Impurity in Milnacipran Hydrochloride Active Pharmaceutical Ingredient. | en_US |
dc.type | Faculty Papers | en_US |
Appears in Collections: | Faculty Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
IPFP0119.pdf | IPFP0119 | 464.57 kB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.